Read More

Novo Nordisk/Eli Lilly’s Weight Loss Drugs Does Not Cause Suicidal Behaviors – After FDA, European Medicines Agency Says

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough reviews and data analyses, no changes to product information were deemed necessary.

AZN

Read More

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement With Mexican Pharmaceutical Manufacturer For Initial Development And Production Of Its Mango Erectile Dysfunction Products

Signifies the first major step towards the application process for the certification of itsMango ED oral dissolvable products by Mexico's health governing agency, COFEPRISDallas, Texas, April 12, 2024 (GLOBE NEWSWIRE) --

MGRX

Read More

Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

IPSC

Read More

Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.

ALPN